Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address medical needs with breakthrough innovations. Oculis’s differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments.

Products, services, technology

OCS-01 being developed in DME and inflammation and pain following ocular surgery
OCS-02 being developed for Dry Eye Disease and Uveitis
OCS-05 being developed for neuro-retina diseases
Pre-clinical candidates for retinal disorders and for ocular inflammation

Location

EPFL, 1015 Lausanne, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    10-19
Key business